SCHEMBL7575729

SCHEMBL7575729

O=S(=O)(Cl)OCCCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8720601 0.83 CA1 (0.33)
SCHEMBL11730088 0.82
SCHEMBL10873887 0.80 CA1 (0.52)
SCHEMBL1607820 0.78 CA1 (0.42)
SCHEMBL63094 0.73
SCHEMBL11883897 0.73
SCHEMBL10629834 0.73
SCHEMBL3270913 0.73
SCHEMBL1524940 0.73
SCHEMBL11155659 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124190-A1 METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2026-05-07 US disclosed
US-12441723-B2 Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations RIGEL PHARMACEUTICALS, INC. (US) 2025-10-14 US disclosed
US-12357623-B2 Method for treating a disease or condition using a pyrazole compound or formulation thereof RIGEL PHARMACEUTICALS, INC. (US) 2025-07-15 US disclosed
US-20240382470-A1 Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus RIGEL PHARMACEUTICALS INC (US) 2024-11-21 US disclosed
CN-118510771-A IRAK inhibitors for the treatment of conditions associated with cytokine release associated with respiratory viral infection 里格尔药品股份有限公司 2024-08-16 CN disclosed
EP-4399208-A1 IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS Rigel Pharmaceuticals, Inc. (US) 2024-07-17 EP disclosed
US-20230399326-A1 PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS RIGEL PHARMACEUTICALS, INC. (US) 2023-12-14 US disclosed
WO-2023038815-A1 IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS RIGEL PHARMACEUTICALS, INC. (US) 2023-03-16 WO disclosed
US-20220306620-A1 PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS RIGEL PHARMACEUTICALS, INC. (US) 2022-09-29 US disclosed
US-20220288047-A1 METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2022-09-15 US disclosed
CN-106102747-A NO-releasing nitrooxy-chromene conjugates 欧利瑟斯制药公司 2016-11-09 CN disclosed
WO-2015109014-A1 NO-RELEASING NONOATE(OXYGEN-BOUND)CHROMENE CONJUGATES Euclises Pharmaceuticals, Inc. (US) 2015-07-23 WO disclosed
US-20150197500-A1 NO-RELEASING GUANIDINE-CHROMENE CONJUGATES EUCLISES PHARMACEUTICALS INC (US) 2015-07-16 US disclosed
US-20020082420-A1 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-06-27 US disclosed
EP-0334853-B1 SOFT STEROIDS HAVING ANTI-INFLAMMATORY ACTIVITY BODOR, Nicholas S. (US) 1993-06-09 EP disclosed
EP-0334853-A4 SOFT STEROIDS HAVING ANTI-INFLAMMATORY ACTIVITY. BODOR NICHOLAS S 1990-02-26 EP disclosed
EP-0334853-A1 SOFT STEROIDS HAVING ANTI-INFLAMMATORY ACTIVITY BODOR, Nicholas S. (US) 1989-10-04 EP disclosed
WO-1989003390-A1 SOFT STEROIDS HAVING ANTI-INFLAMMATORY ACTIVITY BODOR NICHOLAS S (US) 1989-04-20 WO disclosed
US-4710495-A Soft steroids having anti-inflammatory activity OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1987-12-01 US disclosed
US-4388246-A THERMAL SPLITTING OF CARBAMATES BAYER AKTIENGESELLSCHAFT (DE) 1983-06-14 US disclosed